Life sciences company seals exclusive overseas supply deal
Wakefield-based ProBiotix Health, a life sciences business developing probiotics to support cardiometabolic health, has secured a new supply agreement in the Far East.
It has entered into an exclusive long-term partnership agreement with Kemin China Technology Co Ltd (KCG).
The deal will allow KCG to sell the West Yorkshire-headquartered company’s proprietary probiotic strain LPLDL®, as a cardiometabolic health supplement ingredient in China, Hong Kong and Macau, with the opportunity to discuss expansion into other regions.
ProBiotix will supply its raw materials in bulk to KCG, whereupon LPLDL® will be marketed and sold under a co-branding arrangement.
ProBiotix notes that over 330 million people in China are affected by cardiovascular disease, with two out of five deaths caused by the condition. It adds the Chinese probiotic supplement retail market, was valued in 2024 at $2.3bn, and is projected to reach $3.6bn by 2028.
The parent company of KCG is Kemin Industries, a multinational international ingredients supplier.
Founded in 1961, Kemin is headquartered in Iowa in the US, has revenues of more than $1bn, and has more than 500 patents and applications.
Steen Andersen, CEO of ProBiotix, said: “With the huge prevalence of cardiovascular disease in China, we are pleased to have secured this important, long-term collaboration with KCG, which should provide a significant and sustainable revenue stream to both companies.
“It provides scope to expand our sales of LPLDL® in what is a key market for us, through a well-established partner with a strong industry brand.
“It also complements the recent agreement between ProBiotix and Dancare, who sell and distribute finished products.”
Dr Gan Zhilin, president of KCG, added: “We are glad to partner with ProBiotix in cardiovascular health to address this global health challenge.
“Relying on ProBiotix’s cutting-edge research in the field of probiotic technology and remarkable achievements in improving cardiovascular health, combined with the rich resources of KCG in the Chinese market, we are committed to providing consumers with more efficient and safer cardiovascular health solutions.
“This co-operation not only realises the strong combination of technological advantages of both sides, but also the firm practice of our ‘healthy China’ strategy.”
For more information and the source, visit: Life sciences company seals exclusive overseas supply deal | TheBusinessDesk.com